• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
.[J].Journal Of Pharmaceutical Research,2013,32(9):506[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2818times   Download 2179次 QR Code for this article
Scan with your phone!
FDA批准新型SNRI类药物Fetzima
Font:Larger+|Default|Smaller-
()
摘要:
关键词:  米那普仑  FDA  Fetzima  SNRI  缓释胶囊  色胺  再摄取  去甲肾上腺素  抑制作用  抑郁性障碍
DOI:10.13506/j.cnki.jpr.2013.09.012
基金项目:
()
Abstract:
Key words:  
Today's Visits:487    Total Visits:2383201
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.